Recce Pharmaceuticals Ltd (RECEF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Recce Pharmaceuticals Ltd (RECEF) trades at $0.22 with AI Score 50/100 (Grade B). Recce Pharmaceuticals Ltd. is an Australian biotechnology company focused on developing and commercializing synthetic anti-infectives. Market cap: $67.3M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RECEF: RECEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RECEF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RECEF: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Recce Pharmaceuticals Ltd (RECEF) Healthcare & Pipeline Overview
Recce Pharmaceuticals Ltd. is a biotechnology firm specializing in synthetic anti-infectives to combat antibiotic-resistant bacteria and viral infections. With a focus on RECCE 327 for sepsis and RECCE 529 for viral infections, the company aims to address unmet needs in infectious disease treatment across Australia, the US, and the UK.
What Is the Investment Thesis for RECEF?
Recce Pharmaceuticals presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on novel synthetic anti-infectives addresses a critical global health need, particularly with the rise of antibiotic-resistant bacteria. RECCE 327's potential to treat sepsis, a life-threatening condition, is a key value driver. Successful clinical trials and regulatory approvals could lead to significant market adoption. However, the company's negative profit margin of -5378.1% and gross margin of -277.3% highlight its reliance on future product success. Upcoming clinical trial results for RECCE 327 and RECCE 529 are crucial catalysts. Potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's small market cap of $67.3M reflects its early stage and associated risks.
Based on FMP financials and quantitative analysis
RECEF Key Highlights
Lead candidate RECCE 327 targets blood infections and sepsis, addressing a critical unmet need in the treatment of antibiotic-resistant bacteria.
- RECCE 529 is being developed as a broad-spectrum anti-infective for viral infections, expanding the company's potential market reach.
- The company operates in Australia, the United States, and the United Kingdom, providing access to key pharmaceutical markets.
- Recce Pharmaceuticals changed its name from Recce Limited in November 2017, signaling a strategic shift towards pharmaceutical development.
- The company's market capitalization is $0.08 billion as of 2026-03-16, reflecting its early stage and growth potential.
Who Are RECEF's Competitors?
RECEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADOCY Adocia S.A. | $11.80 | +0.00% | $170M | 56 |
| ADOIF Adocia S.A. | $8.87 | +0.00% | $104M | 52 |
| AMCY ACS Global, Inc. | $3.00 | -40.00% | $171M | 46 |
| AMGXF AnGes, Inc. | $0.36 | +0.00% | $143M | 59 |
| BRNHF Broncus Holding Corporation | $0.08 | +0.00% | $42.1M | 50 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RECEF's Key Strengths?
Novel synthetic anti-infective technology.
- Lead candidate targeting a critical unmet need in sepsis treatment.
- Experienced management team with expertise in drug development.
- Operations in key pharmaceutical markets (Australia, US, UK).
What Are RECEF's Weaknesses?
Negative profit margin and gross margin.
- Reliance on future product success.
- Limited financial resources.
- High risk of clinical trial failures.
What Could Drive RECEF Stock Higher?
RECEF catalyst: Clinical trial results for RECCE 327 in sepsis treatment are expected in late 2026, which could significantly impact the company's valuation.
- Clinical trial results for RECCE 529 in viral infections are anticipated in early 2027, potentially expanding the company's market opportunities.
- Continued research and development efforts to expand the company's pipeline of anti-infective therapies.
- Strategic partnerships and collaborations with pharmaceutical companies to accelerate commercialization efforts.
- Regulatory approvals for RECCE 327 and RECCE 529 in key markets (US, Europe, Australia).
What Are the Key Risks for RECEF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for RECCE 327 or RECCE 529 could significantly impact the company's prospects.
- Regulatory hurdles and delays in obtaining approvals for its drug candidates.
- Competition from established pharmaceutical companies with greater resources.
- The company's negative profit margin and gross margin highlight its reliance on future product success.
- The need for additional funding to support ongoing research and development efforts.
What Are the Growth Opportunities for RECEF?
- RECCE 327 has the potential to capture a significant share of this market if it demonstrates superior efficacy and safety in clinical trials. The timeline for commercialization depends on successful clinical trial outcomes and regulatory approvals, potentially within the next 3-5 years. Recce's competitive advantage lies in its novel synthetic anti-infective approach, which may overcome resistance mechanisms.
- RECCE 529 for Viral Infections: The market for antiviral therapies is also substantial, driven by the emergence of new viral threats and the increasing prevalence of chronic viral infections. RECCE 529's broad-spectrum activity could make it a valuable treatment option for a range of viral infections. The timeline for commercialization depends on successful clinical trial outcomes and regulatory approvals, potentially within the next 5-7 years. Recce's competitive advantage lies in its unique mechanism of action, which may offer advantages over existing antiviral therapies.
- Expansion into New Geographic Markets: Recce Pharmaceuticals can expand its geographic reach beyond Australia, the United States, and the United Kingdom by partnering with pharmaceutical companies in other regions. This would allow the company to access new markets and increase its revenue potential. The timeline for geographic expansion depends on securing partnerships and obtaining regulatory approvals in new markets, potentially within the next 2-3 years. Recce's competitive advantage lies in its innovative technology and its ability to address unmet needs in infectious disease treatment.
- Development of New Anti-Infective Candidates: Recce Pharmaceuticals can leverage its expertise in synthetic anti-infectives to develop new drug candidates targeting other infectious diseases. This would diversify the company's product pipeline and reduce its reliance on RECCE 327 and RECCE 529. The timeline for developing new drug candidates depends on research and development efforts and clinical trial outcomes, potentially within the next 5-10 years. Recce's competitive advantage lies in its proprietary technology platform and its ability to identify and develop novel anti-infective agents.
- Strategic Partnerships and Collaborations: Recce Pharmaceuticals can form strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and government agencies to accelerate the development and commercialization of its products. This would provide access to additional funding, expertise, and resources. The timeline for forming partnerships and collaborations depends on identifying suitable partners and negotiating agreements, potentially within the next 1-2 years. Recce's competitive advantage lies in its innovative technology and its ability to attract partners who are interested in developing new anti-infective therapies.
What Are RECEF's Competitive Advantages?
- Proprietary synthetic anti-infective technology platform.
- Strong patent protection for its drug candidates.
- Focus on addressing unmet needs in infectious disease treatment.
- Expertise in developing and commercializing anti-infective therapies.
What Does RECEF Do?
Recce Pharmaceuticals Ltd, established in 2007 and headquartered in Sydney, Australia, is a biotechnology company dedicated to the research, development, and commercialization of novel synthetic anti-infectives. Originally named Recce Limited, the company rebranded in November 2017 to Recce Pharmaceuticals Ltd, reflecting its strategic focus on pharmaceutical solutions. The company's primary focus is addressing the global threat of antibiotic-resistant bacteria and emerging viral infections. Their lead candidate, RECCE 327, is being developed as a treatment for blood infections and sepsis, targeting both E. coli and S. aureus bacteria, including their superbug forms. Furthermore, Recce is developing RECCE 529, a broad-spectrum synthetic anti-infective designed to combat various viral infections. RECCE 435, another synthetic polymer anti-infective, is also in their pipeline. Recce Pharmaceuticals operates across Australia, the United States, and the United Kingdom, seeking to bring innovative solutions to global healthcare challenges. The company aims to provide effective treatments against evolving infectious diseases.
What Products and Services Does RECEF Offer?
- Researches and develops synthetic anti-infectives.
- Focuses on treatments for blood infections and sepsis.
- Develops therapies for viral infections.
- Aims to combat antibiotic-resistant bacteria.
- Conducts clinical trials to evaluate drug candidates.
- Seeks regulatory approvals for its products.
- Commercializes anti-infective products in global markets.
How Does RECEF Make Money?
- Develops and patents novel synthetic anti-infectives.
- Out-licenses or partners with pharmaceutical companies for commercialization.
- Generates revenue through product sales, licensing fees, and milestone payments.
What Industry Does RECEF Operate In?
Recce Pharmaceuticals operates within the biotechnology industry, which is characterized by high innovation, long development cycles, and significant regulatory oversight. The increasing prevalence of antibiotic-resistant bacteria and emerging viral threats drives demand for new anti-infective therapies. The market for sepsis treatment is substantial, with a high mortality rate and significant healthcare costs. Competition includes established pharmaceutical companies and other biotechnology firms developing novel anti-infectives. Recce's synthetic anti-infective approach offers a potential advantage in terms of efficacy and safety.
Who Are RECEF's Key Customers?
- Hospitals and healthcare providers treating patients with sepsis and blood infections.
- Patients suffering from viral infections.
- Pharmaceutical companies seeking to expand their anti-infective product portfolios.
- Government agencies and public health organizations.
Recce Pharmaceuticals Ltd Financial Trajectory
Recce Pharmaceuticals Ltd (RECEF) reported $563K in revenue for Q2 2025, a decline of 91.9% compared to the prior quarter. The company recorded a net loss of $13.7M, with diluted EPS of $-0.06. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
Company Profile
Recce Pharmaceuticals Ltd operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sydney, AU. The company is led by CEO James Hamilton-Bray Graham. RECEF has traded publicly since 2022.
How Recce Pharmaceuticals Ltd Is Valued
Recce Pharmaceuticals Ltd carries a market capitalization of $67.3M, placing it in the micro-cap category. Relative to its peer group, RECEF's quantitative score of 50/100 is roughly in line with the peer average of 53/100.
Key Financial Metrics
Return on equity for Recce Pharmaceuticals Ltd stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. RECEF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Recce Pharmaceuticals Ltd's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Recce Pharmaceuticals Ltd revenue of about $4.8M for fiscal 2026, with EPS near $-0.06.
RECEF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Recce's pipeline, indicating potential positive developments ahead.
- Community sentiment has shifted positively, with increased discussions around the company's innovative drug candidates.
- Recent news of collaborations with research institutions has sparked optimism about advancing their clinical trials.
- The growing interest in the biotech sector, especially in novel therapies, aligns well with Recce's focus on addressing unmet medical needs.
Bear Case
- Concerns about the slow pace of clinical trial results have dampened enthusiasm among some investors.
- Social sentiment reflects skepticism regarding the company's ability to secure additional funding for ongoing research.
- Recent market volatility in biotech stocks has led to cautious sentiment, with some traders wary of potential downturns.
- The competitive landscape in the pharmaceutical industry poses risks, as established players may overshadow Recce's advancements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $562,520 | -$14M | -$0.06 |
| Q4 2024 | $7M | -$8M | -$0.03 |
| Q2 2024 | $3M | -$10M | -$0.05 |
Based on FMP financials and quantitative analysis
RECEF Latest News
No recent news available for RECEF.
RECEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RECEF.
Price Targets
Wall Street price target analysis for RECEF.
RECEF MoonshotScore
What does this score mean?
The MoonshotScore rates RECEF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James Hamilton-Bray Graham
CEO
James Hamilton-Bray Graham serves as the Chief Executive Officer of Recce Pharmaceuticals Ltd. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. He has held various leadership positions in both public and private companies, contributing to the advancement of innovative healthcare solutions. His expertise spans across drug development, commercialization, and corporate finance.
Track Record: Under James Hamilton-Bray Graham's leadership, Recce Pharmaceuticals has focused on advancing its pipeline of synthetic anti-infectives, particularly RECCE 327 and RECCE 529. Key milestones include progressing RECCE 327 through clinical trials and expanding the company's intellectual property portfolio. He has also overseen strategic partnerships and collaborations to support the company's growth and development.
RECEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Recce Pharmaceuticals Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face less stringent listing requirements, resulting in a higher risk profile for investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- OTC Other tier status indicates higher risk compared to listed exchanges.
- Potential for limited regulatory oversight.
- The company's financial stability may be uncertain.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company is actively developing novel anti-infective therapies.
- Recce Pharmaceuticals has a portfolio of patents related to its technology.
- The company is conducting clinical trials to evaluate its drug candidates.
- Recce Pharmaceuticals has operations in multiple countries (Australia, US, UK).
- The company has a dedicated management team focused on drug development.
Recce Pharmaceuticals Ltd Healthcare Stock: Key Questions Answered
What does the AI Score mean for RECEF?
RECEF holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Recce Pharmaceuticals Ltd. is an Australian biotechnology company focused on developing and commercializing synthetic anti-infectives. Their lead candidate, RECCE 327, targets blood infections …
What does Recce Pharmaceuticals Ltd do?
Recce Pharmaceuticals Ltd is a biotechnology company focused on developing and commercializing novel synthetic anti-infectives. Their primary focus is on addressing the global threat of antibiotic-resistant bacteria and emerging viral infections. The company's lead candidate, RECCE 327, is being developed as a treatment for blood infections and sepsis, targeting both E. coli and S. aureus bacteria, including their superbug forms.
What do analysts say about RECEF stock?
As of 2026-03-16, there is no readily available analyst consensus on RECEF stock. The company's financial metrics, including a negative P/E ratio of -4.49, a profit margin of -5378.1%, and a gross margin of -277.3%, reflect its early stage and ongoing research and development investments.
What are the main risks for RECEF?
The main risks for Recce Pharmaceuticals Ltd include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's success depends on the successful development and commercialization of its drug candidates, which is subject to significant uncertainty. Clinical trials may fail to demonstrate efficacy or safety, and regulatory agencies may not approve the company's products.
What are the key factors to evaluate for RECEF?
Recce Pharmaceuticals Ltd (RECEF) holds an AI score of 50/100 (moderate). Recce Pharmaceuticals presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does RECEF data refresh on this page?
RECEF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RECEF's recent stock price performance?
Recce Pharmaceuticals Ltd (RECEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel synthetic anti-infective technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RECEF overvalued or undervalued right now?
Recce Pharmaceuticals Ltd (RECEF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RECEF before investing?
Before investing in Recce Pharmaceuticals Ltd (RECEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst consensus is not available.
- OTC market data may be limited.